Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. ET and had been down as much as 38.7% earlier in the session.
GERN earnings call for the period ending December 31, 2024.
These biotech companies’ strategic advancements are setting them up for long-term success.
For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic syndromes...
GERN earnings call for the period ending September 30, 2024.
This biotech company currently has an approved product on the market. However, there is more to the story than meets the eye.
GERN earnings call for the period ending June 30, 2024.